Drugs that contain Glasdegib Maleate

1. List of Daurismo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8148401 PFIZER Benzimidazole derivatives
Jan, 2031

(7 years from now)

US10414748 PFIZER Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate
Apr, 2036

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8431597 PFIZER Benzimidazole derivatives
Jun, 2028

(5 years from now)

US11168066 PFIZER Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate
Apr, 2036

(13 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 21, 2023
Orphan Drug Exclusivity (ODE) Nov 21, 2025

NCE-1 date: November, 2022

Market Authorisation Date: 21 November, 2018

Treatment: Use, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (aml) in adult patients who are >= 75 years old or who have comorbidities that preclude use of intensive induction chemotherapy

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic